Skip to content

Homepage

Author: Eton Pharmaceuticals

Posted Date:

May 22, 2026

Eton Pharmaceuticals Expands Rare Disease Portfolio Through Agreement for U.S. Commercialization Rights to IMPAVIDO® (miltefosine)

Eton Pharmaceuticals

May 22, 2026
Eton Pharmaceuticals Expands Rare Disease Portfolio Through Agreement for U.S. Commercialization Rights to IMPAVIDO® (miltefosine)

Eton Pharmaceuticals

May 20, 2026
Eton Pharmaceuticals Reports First Quarter 2026 Financial Results

Eton Pharmaceuticals

May 14, 2026
Eton Pharmaceuticals to Participate in Upcoming Investor Conferences

Eton Pharmaceuticals

May 12, 2026
Eton Pharmaceuticals to Report First Quarter 2026 Financial Results on Thursday, May 14, 2026

Eton Pharmaceuticals

May 4, 2026
Eton Pharmaceuticals relaunches HEMANGEOL® (propranolol) Oral Solution with Eton Cares and Exclusive Specialty Pharmacy Distribution

Eton Pharmaceuticals

May 1, 2026
Eton Pharmaceuticals Announces Initiation of Clinical Study for Product Candidate ET-700

Eton Pharmaceuticals

April 27, 2026
Eton Pharmaceuticals Announces CFO Succession Plan

Eton Pharmaceuticals

April 16, 2026
Eton Pharmaceuticals Reports Fourth Quarter and Full Year 2025 Financial Results

Eton Pharmaceuticals

March 19, 2026
Eton Pharmaceuticals to Report Fourth Quarter and Full Year 2025 Financial Results on Thursday, March 19, 2026

Eton Pharmaceuticals

March 3, 2026

1 2